Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)
Authors' conclusion
In this post hoc analysis, improvements in HbA1c and weight loss were consistent and significantly higher with tirzepatide, regardless of baseline β-cell function and insulin resistance, compared with semaglutide.
Study context
- Population
- Participants with T2D, 128 sites in 8 countries
- Participants
- 1,879 participants
- Comparison
- Once-weekly tirzepatide vs semaglutide 1 mg
- Primary endpoint
- Change in HOMA2-B, HOMA2-IR, fasting glucagon, fasting C-peptide and fasting insulin
- Follow-up
- Week 40
Methodological detailspost hoc analysis, phase 3, 128 sites in 8 countries
- Post hoc analysis
- Phase 3
- 128 sites in 8 countries
Primary result
As reported in the abstract
Increase in HOMA2-B
Tirzepatide
96.9-120.4%
Semaglutide 1 mg
84.0%
P < 0.05
Further findings
| Outcome | Tirzepatide | Semaglutide 1 mg | P value |
|---|---|---|---|
| Reduction in HOMA2-IR · week 40Greater reduction with all tirzepatide doses | 15.5%-24.0% | 5.1% | P < 0.05 |
| Fasting C-peptide change (tirzepatide 10 and 15 mg) · week 40 | 5.2%-6.0% | 3.3% | P < 0.05 |
| Fasting glucagon reduction (tirzepatide 10 and 15 mg) · week 40 | 53.0%-55.3% | 47.7% | P < 0.05 |
- Fasting C-peptide change (tirzepatide 10 and 15 mg): reduction with tirzepatide 10 and 15 mg vs increase with semaglutide
HbA1c and body weight reductions by baseline HOMA2-B and HOMA2-IR quartile
- HbA1c and body weight reductions greater with all tirzepatide doses than semaglutide within each HOMA2-B and HOMA2-IR baseline quartile
Original publication
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). J Clin Endocrinol Metab. Published 22 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →